High-grade gliomas with MMR deficiencies are recognized to confer poorer prognosis due to resistance to the current standard-of-care chemotherapy (temozolomide) but are considered to respond better to novel therapies like immune checkpoint inhibitors [121,122]. The gene discussed is MRC1; the disease is glioma.